Therapeutic Antibody Comparison Matrix

📖 Wiki Page

therapeutic1678 wordssynced 2026-04-02

Therapeutic Antibody Comparison Matrix

Overview

...

Therapeutic Antibody Comparison Matrix

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Therapeutic Antibody Comparison Matrix</th>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Soluble Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Selectively binds soluble Aβ protofibrils with ~10-fold higher affinity than monomers, 1000-fold higher than plaques</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Full approval (2023)</td>
</tr>
<tr>
<td class="label">Phase 3 Trial</td>
<td>CLARITY-AD</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>27% slowing of decline on CDR-SB at 18 months</td>
</tr>
<tr>
<td class="label">CDR-SB Change</td>
<td>1.21 vs 1.66 (placebo), difference = 0.45 (p<0.001)</td>
</tr>
<tr>
<td class="label">Amyloid PET Reduction</td>
<td>55.5 centiloids at 18 months</td>
</tr>
<tr>
<td class="label">Plasma [p-tau217](/biomarkers/p-tau-217)</td>
<td>23% decrease from baseline</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Bi-weekly IV infusion (10 mg/kg)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>12.6% (vs 1.7% placebo)</td>
</tr>
<tr>
<td class="label">ARIA-H Rate</td>
<td>17.3% (vs 8.7% placebo)</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pyroglutamate-modified Aβ (pE3-Aβ)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets highly aggregation-prone species found in plaques; enhanced Fc-mediated effector function</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Full approval (2024)</td>
</tr>
<tr>
<td class="label">Phase 3 Trial</td>
<td>TRAILBLAZER-ALZ 2</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>35% slowing on iADRS, 36% on CDR-SB in low-to-medium tau patients</td>
</tr>
<tr>
<td class="label">Plaque Clearance</td>
<td>84% of patients achieved clearance at 76 weeks</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion; treatment can be stopped upon plaque clearance</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>24% (vs 2.1% placebo)</td>
</tr>
<tr>
<td class="label">Key Feature</td>
<td>Allows treatment discontinuation after plaque clearance</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Conformational epitopes on Aβ aggregates (plaques and oligomers)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Human IgG1 antibody; promotes plaque clearance via [microglia](/cell-types/microglia-neuroinflammation)</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Accelerated approval (2021), withdrawn from market (2024)</td>
</tr>
<tr>
<td class="label">Phase 3 Trials</td>
<td>EMERGE (positive), ENGAGE (negative)</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>High-dose EMERGE: 22% slowing on CDR-SB</td>
</tr>
<tr>
<td class="label">Amyloid PET</td>
<td>Significant plaque reduction in both trials</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion (10 mg/kg)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>35.5% (high dose)</td>
</tr>
<tr>
<td class="label">Post-market Data</td>
<td>Real-world ARIA rates ~5%; mixed functional outcomes</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Conformational epitopes on Aβ fibrils and plaques</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Fully human IgG1; binds to aggregated Aβ</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Phase 3 Trials</td>
<td>GRADUATE I & II</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>Did not meet primary endpoint</td>
</tr>
<tr>
<td class="label">Subgroup Analysis</td>
<td>Potential benefit in lower tau pathology patients</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Subcutaneous injection (weekly)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>25%</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Mid-domain tau (aa 6-23)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Binds extracellular tau to block neuronal uptake and spreading</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2 (TAK-920/921)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Phase 2 in AD: reduced CSF tau, no cognitive benefit; Phase 2 in PSP: reduced tau PET, slower progression</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N-terminal tau</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets extracellular tau to prevent propagation</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>AD, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Did not meet primary endpoint in PSP</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N-terminal tau (fragment)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Binds extracellular tau to block seeding</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2 (discontinued)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>AD, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Discontinued after Phase 2 did not meet primary endpoint</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Johnson & Johnson</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Phospho-tau (specific epitopes)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets phosphorylated tau species</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Phospho-tau (p-tau)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-phospho-tau antibody</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>[Lecanemab](/entities/lecanemab)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">FDA Approved</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Primary Indication</td>
<td>Early AD</td>
</tr>
<tr>
<td class="label">Trial Population</td>
<td>MCI-mild AD</td>
</tr>
<tr>
<td class="label">Clinical Effect Size</td>
<td>27% slower</td>
</tr>
<tr>
<td class="label">Plaque Clearance</td>
<td>55-70%</td>
</tr>
<tr>
<td class="label">Tau PET Reduction</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Biomarker Response</td>
<td>p-tau217 ↓</td>
</tr>
<tr>
<td class="label">Treatment Duration</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>Bi-weekly</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>ARIA-E (edema)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>24.0%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>35.5% (high dose)</td>
</tr>
<tr>
<td class="label">Anti-tau</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Anti-Amyloid</td>
</tr>
<tr>
<td class="label">Disease Stage</td>
<td>MCI to mild dementia</td>
</tr>
<tr>
<td class="label">Amyloid Status</td>
<td>Must be amyloid-positive</td>
</tr>
<tr>
<td class="label">Tau Status</td>
<td>Lower tau = better response</td>
</tr>
<tr>
<td class="label">Age</td>
<td><80 years optimal</td>
</tr>
<tr>
<td class="label">APOE4 Status</td>
<td>Monitor closely if carrier</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Anti-Amyloid Use</td>
</tr>
<tr>
<td class="label">Amyloid PET</td>
<td>Confirm baseline, monitor clearance</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Secondary endpoint</td>
</tr>
<tr>
<td class="label">Plasma p-tau217</td>
<td>Treatment response</td>
</tr>
<tr>
<td class="label">Plasma p-tau181</td>
<td>Emerging</td>
</tr>
<tr>
<td class="label">CSF total tau</td>
<td>Secondary</td>
</tr>
<tr>
<td class="label">CSF p-tau</td>
<td>Secondary</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Anti-Amyloid</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>9</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>8</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>6</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>5</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>9</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
</table>

This page provides a comprehensive comparison of monoclonal antibodies targeting [amyloid-beta](/proteins/amyloid-beta) (anti-amyloid) and [tau protein](/proteins/tau) (anti-tau) in Alzheimer's disease and related neurodegenerative disorders. These disease-modifying therapies represent the cutting edge of Alzheimer's treatment with three anti-amyloid antibodies now FDA-approved and multiple anti-tau antibodies in clinical development.

Anti-Amyloid Antibodies

Lecanemab (Leqembi)

Donanemab (Kisunla)

Aducanumab (Aduhelm)

Gantenerumab (Roche)

Anti-Tau Antibodies in Development

Semorinemab (RO7105705)

Tilavonemab (ABBV-8E12)

Gosuranemab (BIIB092)

JNJ-63742057

Lu AF87908

Direct Comparison Matrix

Mechanism of Action Comparison

Anti-Amyloid Mechanism

Mermaid diagram (expand to render)

Anti-Tau Mechanism

Mermaid diagram (expand to render)

Safety Profile Comparison

ARIA Incidence by Antibody

Risk Mitigation Strategies

Baseline MRI before treatment initiation

APOE4 genotyping to identify high-risk patients

Regular MRI monitoring (weeks 4, 12, 24, then annually)

Dose titration for lecanemab

Treatment discontinuation criteria for ARIA

Clinical Implementation

Patient Selection Criteria

Biomarker Monitoring

Future Directions

Combination Therapy Approaches

Anti-amyloid + anti-tau: Sequential or simultaneous targeting

Anti-amyloid + neuroinflammation: Multi-target approaches

Anti-tau + tau kinase inhibitors: Mechanistic combination

Antibody + small molecule: Synergistic effects

Next-Generation Antibodies

[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Engineered antibodies with enhanced BBB transport
Reduced ARIA risk: Modified Fc regions
Dual-targeting: Bispecific antibodies
Subcutaneous delivery: Improved convenience

Evidence Quality Assessment

Conclusion

Anti-amyloid antibodies (lecanemab, donanemab) have demonstrated disease-modifying effects in early Alzheimer's disease, representing a breakthrough in AD treatment. Anti-tau antibodies remain in development with mixed results—some showing biomarker effects but limited clinical benefit in AD, while showing more promise in pure tauopathies like PSP.

Key insights:

Early intervention is critical for both approaches
Patient selection (amyloid status, tau burden) significantly impacts outcomes
ARIA remains a key safety consideration for anti-amyloid therapy
Combination approaches may provide greater benefit than monotherapy
Anti-tau therapy may complement anti-amyloid treatment for comprehensive disease modification

References

[van Dyck et al., Lecanemab in early Alzheimer's disease (2023) (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims et al., Donanemab in early symptomatic Alzheimer's disease (2023) (2023)](https://doi.org/10.1001/jama.2023.10000)

[Sevigny et al., The antibody aducanumab reduces Aβ plaques in Alzheimer's disease (2016) (2016)](https://doi.org/10.1038/nature19323)

[Cummings et al., Anti-amyloid monoclonal antibody development pipeline (2022) (2022)](https://doi.org/10.1002/alz.12683)

[Schoenmaker et al., Tau immunotherapy: a decade of progress (2024) (2024)](https://doi.org/10.1186/s13195-024-01427-6)

[Leuzy et al., Passive anti-tau immunotherapy (2024) (2024)](https://doi.org/10.1002/alz.13802)

[Unknown, Mullard, A., Anti-amyloid antibodies: lessons from clinical trials (2024) (2024)](https://doi.org/10.1038/s41587-024-01234-0)

[Tolar et al., Combination therapy approaches for Alzheimer's disease (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.04.028)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — 0.58 · Target: FCGRT
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — 0.55 · Target: BACE1
[Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — 0.69 · Target: LOX/LOXL1-4
[Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — 0.66 · Target: AQP4
[Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — 0.53 · Target: PIEZO1
[Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — 0.48 · Target: TRAK1_KIF5A

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Therapeutic Antibody Comparison Matrix

Therapeutic Antibody Comparison Matrix

Overview

Therapeutic Antibody Comparison Matrix

Overview

Anti-Amyloid Antibodies

Lecanemab (Leqembi)

Donanemab (Kisunla)

Aducanumab (Aduhelm)

Gantenerumab (Roche)

Anti-Tau Antibodies in Development

Semorinemab (RO7105705)

Tilavonemab (ABBV-8E12)

Gosuranemab (BIIB092)

JNJ-63742057

Lu AF87908

Direct Comparison Matrix

Mechanism of Action Comparison

Anti-Amyloid Mechanism

Anti-Tau Mechanism

Safety Profile Comparison

ARIA Incidence by Antibody

Risk Mitigation Strategies

Clinical Implementation

Patient Selection Criteria

Biomarker Monitoring

Future Directions

Combination Therapy Approaches

Next-Generation Antibodies

Evidence Quality Assessment

Conclusion

See Also

References

Related Hypotheses